Article
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
15 Jan 2015
Abstract excerpt
Cancer cells rely on telomerase or the alternative lengthening of telomeres (ALT) pathway to overcome replicative mortality. ALT is mediated by recombination and is prevalent in a subset of human cancers, yet whether it can be exploited therapeutically remains unknown. Loss of the chromatin-remodeling protein ATRX associates with ALT in cancers. Here, we show that ATRX loss compromises cell-cycle regulation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
